Piermont Capital Management Inc. reduced its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 14.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,040 shares of the specialty pharmaceutical company’s stock after selling 2,250 shares during the period. Piermont Capital Management Inc. owned approximately 0.11% of ANI Pharmaceuticals worth $610,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the company. Intrust Bank NA increased its position in ANI Pharmaceuticals by 11.8% during the second quarter. Intrust Bank NA now owns 5,051 shares of the specialty pharmaceutical company’s stock worth $236,000 after purchasing an additional 535 shares during the last quarter. Tudor Investment Corp ET AL increased its position in ANI Pharmaceuticals by 80.4% during the first quarter. Tudor Investment Corp ET AL now owns 8,300 shares of the specialty pharmaceutical company’s stock worth $411,000 after purchasing an additional 3,700 shares during the last quarter. Kennedy Capital Management Inc. acquired a new stake in ANI Pharmaceuticals during the first quarter worth about $4,069,000. Prudential Financial Inc. increased its position in ANI Pharmaceuticals by 1.4% during the first quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock worth $697,000 after purchasing an additional 200 shares during the last quarter. Finally, Chicago Equity Partners LLC increased its position in ANI Pharmaceuticals by 14.2% during the second quarter. Chicago Equity Partners LLC now owns 19,825 shares of the specialty pharmaceutical company’s stock worth $928,000 after purchasing an additional 2,465 shares during the last quarter. 55.86% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) opened at 51.43 on Thursday. The stock has a 50 day moving average of $46.79 and a 200 day moving average of $47.75. The stock has a market cap of $598.54 million, a price-to-earnings ratio of 112.54 and a beta of 3.10. ANI Pharmaceuticals, Inc. has a 1-year low of $42.23 and a 1-year high of $69.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.19. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $43.20 million. ANI Pharmaceuticals had a net margin of 3.35% and a return on equity of 22.70%. The company’s revenue was up 43.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.11 EPS. Equities analysts expect that ANI Pharmaceuticals, Inc. will post $3.84 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/28/piermont-capital-management-inc-decreases-stake-in-ani-pharmaceuticals-inc-anip.html.

Several research firms recently issued reports on ANIP. Canaccord Genuity began coverage on shares of ANI Pharmaceuticals in a research report on Monday, July 31st. They set a “buy” rating and a $60.00 price objective for the company. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Guggenheim restated a “buy” rating and set a $80.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, July 4th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. ANI Pharmaceuticals has an average rating of “Hold” and an average target price of $65.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Stock Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.